A Japanese nationwide survey on the cryopreservation of embryos, oocytes and ovarian tissue for cancer patients.

Published on Oct 1, 2019in Journal of Obstetrics and Gynaecology Research1.392
· DOI :10.1111/JOG.14073
Yuko Sanada1
Estimated H-index: 1
(UTokyo: University of Tokyo),
Miyuki Harada28
Estimated H-index: 28
(UTokyo: University of Tokyo)
+ 15 AuthorsYutaka Osuga62
Estimated H-index: 62
(UTokyo: University of Tokyo)
Aim: The survival rates of cancer patients have greatly improved owing to the advances in oncology. The preservation of fertility in cancer patients is an important task. To determine the reality of cryopreservation of embryos, oocytes and ovarian tissue in cancer patients, large-scale survey analysis was performed in Japan. Methods: We sent 613 Japan Society of Obstetrics and Gynecology-certified assisted reproductive technology institutions a questionnaire about their experience of performing cryopreservation for cancer patients between January 2011 and December 2015. Subsequently, the institutions that conducted cryopreservation for cancer patients were sent a second questionnaire. Results: We received replies from 481 (78.5%) institutions. Among them, 126 (26.2%) conducted cryopreservation for cancer patients. These 126 institutions were sent a second questionnaire. Of these, 108 (85.7%) institutions responded. At the 108 institutions, 1085 embryo or oocyte cryopreservation procedures and 122 ovarian tissue cryopreservation procedures were conducted for cancer patients. Cryopreservation was mainly performed for breast cancer patients (~70%), followed by patients with hematological malignancy. A total of 361 and 19 embryo transfer cycles were performed for patients whose embryos and oocytes were cryopreserved, respectively, and 42 and seven institutions reported pregnancy outcomes after embryo transfer in patients that underwent embryo and oocyte cryopreservation, respectively. However, pregnancy was not observed in the seven cases that underwent ovarian tissue transfer. Conclusion: Indications, age limits and ovarian stimulation protocols for cryopreservation widely varied between the institutions. A national registration system for oncofertility must be established to evaluate the safety and efficacy of the current system.
📖 Papers frequently viewed together
4 Citations
6 Citations
#1Marie-Madeleine Dolmans (UCL: Université catholique de Louvain)H-Index: 63
#2D D Manavella (UCL: Université catholique de Louvain)H-Index: 7
BACKGROUND: Most cancer treatments like chemotherapy, radiotherapy or a combination of both are highly toxic to the gonads, putting girls and young women at risk of premature ovarian insufficiency and subsequent infertility. Non-oncological conditions may also require therapies that put women's reproductive potential at risk. Fertility preservation counseling should therefore be offered to all patients requiring gonadotoxic treatments, and to those who wish to postpone motherhood for social/pers...
36 CitationsSource
#1Miyuki Harada (UTokyo: University of Tokyo)H-Index: 28
#2Yutaka Osuga (UTokyo: University of Tokyo)H-Index: 62
An improvement in the survival rates of cancer patients and recent advancements in assisted reproductive technologies have led to remarkable progress in oncofertility and fertility preservation treatments. Currently, for adults and postpubertal girls, oocyte or embryo cryopreservation is an established method. If their cancer treatment cannot be postponed for 2 weeks, ovarian tissue cryopreservation is offered as an experimental technique. For prepubertal girls, ovarian tissue cryopreservation i...
11 CitationsSource
#1Cesar Diaz-Garcia (University of Valencia)H-Index: 28
#2Javier DomingoH-Index: 11
Last. Antonio Pellicer (University of Valencia)H-Index: 115
view all 9 authors...
Objective To compare the efficacy of oocyte vitrification (OV) with that of ovarian cortex cryopreservation and transplantation (OCT) in women undergoing gonadotoxic treatments. Design Prospective observational cohort study. Setting Not applicable. Patient(s) Candidates for chemo-/radiotherapy who joined our fertility preservation (FP) program were included in this study between 2005 and 2015. One cohort included 1,024 patients undergoing OV; the other cohort included 800 patients undergoing OCT...
74 CitationsSource
#1Marie-Madeleine Dolmans (Cliniques Universitaires Saint-Luc)H-Index: 63
ABSTRACTIntroduction: Ensuring quality of life for increasing numbers of women surviving cancer has become a key challenge. Patients need to be counseled on potential fertility loss resulting from ...
19 CitationsSource
#1Michael Grynberg (Paris Diderot University)H-Index: 22
#2M. PoulainH-Index: 4
Last. Nelly FrydmanH-Index: 29
view all 6 authors...
Are in vitro maturation (IVM) rates of cumulus-oocyte complexes (COCs), retrieved from breast cancer patients seeking urgent fertility preservation (FP) before neoadjuvant chemotherapy, different between those recovered in the follicular or in the luteal phase of the cycle?The present investigation reveals no major difference in the number of COCs recovered or their IVM rates whatever the phase of the cycle at which egg retrieval is performed, suggesting that IVM is a promising tool for breast c...
51 CitationsSource
#1Jayeon Kim (NYMC: New York Medical College)H-Index: 10
#2Volkan Turan (NYMC: New York Medical College)H-Index: 16
Last. Kutluk Oktay (NYMC: New York Medical College)H-Index: 74
view all 3 authors...
Context and Objective: There has been increased attention to the issue of fertility preservation (FP). We aimed to investigate the long-term safety of FP via controlled ovarian stimulation with letrozole supplementation (COSTLES) prior to breast cancer treatment. Design, Setting, and Participants: This is a prospective, nonrandomized, controlled study conducted between the years 2002 and 2014. A total of 337 women diagnosed with stage 3 or less invasive breast cancer were enrolled during a FP co...
106 CitationsSource
#1L. Bastings (Radboud University Nijmegen Medical Centre)H-Index: 9
#2Catharina C.M. Beerendonk (Radboud University Nijmegen Medical Centre)H-Index: 19
Last. Ron Peek (Radboud University Nijmegen Medical Centre)H-Index: 21
view all 8 authors...
BACKGROUND The risk of recurrent oncological disease due to the reintroduction of cancer cells via autotransplantation of cryopreserved ovarian tissue is unknown. METHODS A systematic review of literature derived from MEDLINE, EMBASE and the Cochrane Library was conducted. Studies on follow-up after autotransplantation; detection of cancer cells in ovarian tissue from oncological patients by histology, polymerase chain reaction or xenotransplantation; and epidemiological data on ovarian metastas...
134 CitationsSource
#1Alison W. Loren (NYMC: New York Medical College)H-Index: 1
#2Pamela B. ManguH-Index: 25
Last. Nohr BeckH-Index: 1
view all 11 authors...
Purpose To update guidance for health care providers about fertility preservation for adults and children with cancer.
1,058 CitationsSource
#1Hakan Cakmak (UCSF: University of California, San Francisco)H-Index: 24
#2Mitchell P. Rosen (UCSF: University of California, San Francisco)H-Index: 48
The patients referred for fertility preservation owing to a malignant disease do not represent the typical population of subfertile patients treated in IVF units. Cancer may affect multiple tissues throughout the body and can result in a variety of complications during controlled ovarian stimulation. Determination of the controlled ovarian stimulation protocol and gonadotropin dose for oocyte/embryo cryopreservation requires an individualized assessment. This review highlights the new protocols ...
79 CitationsSource
#1Marie-Madeleine Dolmans (Cliniques Universitaires Saint-Luc)H-Index: 63
#2Valérie Luyckx (Cliniques Universitaires Saint-Luc)H-Index: 12
Last. Tine Greve (Copenhagen University Hospital)H-Index: 9
view all 5 authors...
Ovarian tissue cryopreservation and transplantation is a real option to preserve and restore fertility in young cancer patients. However, there is a concern regarding the possible presence of malignant cells in the ovarian tissue, which could lead to recurrence of the primary disease after reimplantation. A review of the existing literature was done to evaluate the risk of transplanting malignant cells in case of the main malignant indications for ovarian tissue cryopreservation. For ovarian tis...
208 CitationsSource
Cited By6
#1Toshiaki Yasuoka (Ehime University)H-Index: 4
#2Noriyuki Iwama (Tohoku University)H-Index: 14
Last. Yutaka Osuga (UTokyo: University of Tokyo)H-Index: 62
view all 9 authors...
AIM Recent advances in cancer treatment have improved the prognosis of child, adolescent, and young adult (CAYA) cancer survivors. This study aimed to examine the current status of pregnancy outcomes among female cancer survivors in Japan. METHODS The first questionnaire was sent to 633 major tertiary institutions certified by the Japan Society of Obstetrics and Gynecology to identify institutions managing cases of pregnant cancer survivors between January 2011 and December 2015. The second ques...
#1Marisa Kometas (UF: University of Florida)
#2Gregory M. Christman (UF: University of Florida)H-Index: 26
Last. Alice Rhoton-Vlasak (UF: University of Florida)H-Index: 12
view all 4 authors...
After cancer treatment, female survivors often develop ovarian insufficiency or failure. Oocyte and embryo freezing are well-established fertility preservation options, but cannot be applied in pre-pubescent girls, in women with hormone-sensitive malignancies, or when gonadotoxic treatment cannot be delayed. Although ovarian tissue cryopreservation (OTC) has been used to restore fertility and endocrine function, the relative efficacy of its two major protocols, slow freezing and vitrification, r...
#1Sayuri Takahashi (Kyoto University)
#2Akihito Horie (Kyoto University)H-Index: 8
Last. Masaki Mandai (Kyoto University)H-Index: 53
view all 11 authors...
Aim: To ascertain the actual outcomes of oncofertility care in young women to provide more appropriate care. Materials & methods: We analyzed the data of 67 female patients under 43 years of age wh...
#1Sachiyo Okamoto (Okayama University)H-Index: 1
#2Nobuharu Fujii (Okayama University)H-Index: 20
Last. Yutaka Osuga (UTokyo: University of Tokyo)H-Index: 62
view all 8 authors...
BACKGROUND Worldwide, there has been a growing interest in oncofertility issues. In 2017, the Japanese Society of Clinical Oncology published clinical practice guidelines for fertility preservation (FP) in cancer patients. We conducted a questionnaire survey to explore the FP practices among hematologists before the publication of this guideline. METHODS We sent 427 designated cancer hospitals in Japan a questionnaire about FP treatment for patients with hematological malignancies between Januar...
#1Yumi Tsuchida (UTokyo: University of Tokyo)H-Index: 10
#2Miyuki Harada (UTokyo: University of Tokyo)H-Index: 28
Last. Keishi Fujio (UTokyo: University of Tokyo)H-Index: 29
view all 8 authors...
Gonadotoxic therapies, mainly cyclophosphamide, are used for the treatment of various systemic autoimmune diseases. In Japan, the number of patients who undergo gonadotoxic therapy for autoimmune d...